Overview
Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial
Status:
Unknown status
Unknown status
Trial end date:
2020-04-01
2020-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Efficacy and safety of OctaplasLG® administration vs. crystalloids (standard) in patients with septic shock - a randomized, controlled, open-label investigator-initiated pilot trialPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Rigshospitalet, DenmarkCollaborators:
Octapharma
University of Iceland
Criteria
Inclusion Criteria:1. Adult intensive care patients (age ≥ 18 years) AND
2. Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host
response to infection AND
3. Quick SOFA (qSOFA) with two or more of
1. Respiratory rate ≥ 22/min
2. Altered mentation (Glasgow Coma Scale score < 15)
3. Systolic blood pressure ≤ 100mmHg AND
4. Septic shock, defined as a clinical construct of sepsis with persisting hypotension
requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2
mmol/L despite adequate volume resuscitation AND
5. Requiring infusion of noradrenalin 0.10 mcg/kg/min or more to maintain blood pressure
AND
6. Respiratory failure requiring intubation and mechanical ventilation
Exclusion Criteria:
1. Documented refusal of blood transfusion OR
2. Treatment with GPIIb/IIIa inhibitors < 24h from screening OR
3. Withdrawal from active therapy OR
4. Previously within 30 days included in an interventional trial OR
5. Known IgA deficiency with documented antibodies against IgA OR
6. Known hypersensitivity to OctaplasLG®: the active substance, any of the excipients
(Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate or Glycine) or
residues from the manufacturing process (Tri (N-Butyl) Phosphate (TNBP) and Octoxynol
(Triton X-100)) OR
7. Known severe deficiencies of protein S OR
8. Pregnancy (non-pregnancy confirmed by patient being postmenopausal or having a
negative urine-hCG) OR
9. Severe cirrhotic hepatic failure with expected need for treatment with terlipressin